Trial Profile

The Effect of AKST4290 on Choroidal Blood Flow in Patients with Neovascular Age-Related Macular Degeneration

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lazucirnon (Primary)
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms AMD ChBF; STEEL
Sponsors Alkahest

Most Recent Events

09 Jul 2020 According to an Alkahest media release, biomarker analysis is ongoing in this study.
09 Jul 2020 Status changed from recruiting to completed, according to an Alkahest media release.
07 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com